Could fresh human tissues be the missing link for stratified medicine? By Dr David Bunton
Patient stratification in clinical trials is seen as the future, but in order to design smarter trials, how will companies predict which patient sub-populations respond to their drugs during early nonclinical development? This article discusses the need for early patient stratification and looks at possible models to characterise patient "responders" and "non-responders" based on the use of fresh diseased tissues from the target patient population.
Read More »